Osimertinib activates TFEB to trigger hepatocyte cytoplasmic vacuolation-associated cell death
Abstract Osimertinib is a first-line treatment for advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR)-sensitive mutations; however, the severe hepatotoxicity of osimertinib is a challenge that has attracted attention. In this study, we found that osimertinib directly ca...
Gardado en:
| Principais autores: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMC
2026-01-01
|
| Series: | Cell Communication and Signaling |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1186/s12964-026-02688-4 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|